RxDoctor Payments Data

Thomas Biondo, MD

Internal Medicine · Havre de Grace, MDNPI 1649229519

Payments from drug & device makers

$10,461in general payments, 2019–2025

Across 592 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$943
  • Pfizer$909
  • GSK$823
  • AbbVie$743
  • plus $5K from 39 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$10,34099%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,461 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$196,046
Medicare patients
542
Services billed
2,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$77,939
JardianceEmpagliflozin63$71,228
NuplazidPimavanserin Tartrate12$63,455
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$42,044
MounjaroTirzepatide29$31,724
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$31,169
JanuviaSitagliptin Phosphate20$28,183
FarxigaDapagliflozin Propanediol21$26,529
OzempicSemaglutide28$26,224
TrulicityDulaglutide25$24,177
XareltoRivaroxaban21$20,790
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$11,012
Lantus SolostarInsulin Glargine,hum.Rec.Anlog70$7,088
InvokanaCanagliflozin11$6,485
Atorvastatin Calcium321$5,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$909$77,93991 claims
Boehringer IngelheimJardiance$429$71,22863 claims
Acadia Pharmaceuticals IncNuplazid$39$63,45512 claims
Lilly USA, LLCMounjaro, Trulicity$943$55,90154 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,148$37,54133 claims
GSKTrelegy Ellipta, Anoro Ellipta$823$35,44151 claims
MerckJanuvia$209$28,18320 claims
Johnson & JohnsonXarelto, Invokana$192$27,27532 claims
Novo NordiskOzempic$1,143$26,22428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Havre de Grace

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →